KR100314608B1 - Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity - Google Patents

Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity Download PDF

Info

Publication number
KR100314608B1
KR100314608B1 KR1019990018077A KR19990018077A KR100314608B1 KR 100314608 B1 KR100314608 B1 KR 100314608B1 KR 1019990018077 A KR1019990018077 A KR 1019990018077A KR 19990018077 A KR19990018077 A KR 19990018077A KR 100314608 B1 KR100314608 B1 KR 100314608B1
Authority
KR
South Korea
Prior art keywords
extract
quinone reductase
golden
activity
reductase
Prior art date
Application number
KR1019990018077A
Other languages
Korean (ko)
Other versions
KR20000074271A (en
Inventor
박헌주
박형환
김한수
권익부
Original Assignee
한수길
롯데제과주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한수길, 롯데제과주식회사 filed Critical 한수길
Priority to KR1019990018077A priority Critical patent/KR100314608B1/en
Publication of KR20000074271A publication Critical patent/KR20000074271A/en
Application granted granted Critical
Publication of KR100314608B1 publication Critical patent/KR100314608B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 황금 추출물을 퀴논 리덕타아제(Quinone reductase)의 활성 유도물질로 사용하는 방법과 이를 함유하는 음식물에 관한 것으로서, 더욱 상세하게는 황금 추출물이 퀴논 리덕타아제의 활성을 유도하여 암예방 효과를 가짐을 확인하고, 이를 츄잉껌, 캔디, 비스켓, 아이스크림, 음료, 소세지 및 쵸코렛 등의 음식물에 함께 배합함으로써, 청소년, 성인 및 노인층의 광범위한 계층까지 언제 어디서나 늘 간편하게 섭취할 수 있어서 지속적인 음용효과를 기대할 수 있는 암예방 효과를 갖는 황금 추출물이 배합된 음식물에 관한 것이다.The present invention relates to a method of using the gold extract as an activity inducer of quinone reductase (Finone reductase) and to a food containing the same, more specifically, the gold extract induces the activity of quinone reductase to prevent cancer By combining it with foods such as chewing gum, candy, biscuits, ice cream, beverages, sausages and chocolates, it can be easily consumed anytime, anywhere to a wide range of teenagers, adults and the elderly, and expect continuous drinking effects. It relates to a food compound containing a golden extract having a cancer prevention effect.

Description

황금 추출물을 퀴논 리덕타아제의 활성 유도물질로 사용하는 방법과 이를 함유하는 음식물{Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity}Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity}

본 발명은 황금 추출물을 퀴논 리덕타아제(Quinone reductase)의 활성 유도물질로 사용하는 방법과 이를 함유하는 음식물에 관한 것으로서, 더욱 상세하게는 황금 추출물이 퀴논 리덕타아제의 활성을 유도하여 암예방 효과를 가짐을 확인하고, 이를 츄잉껌, 캔디, 비스켓, 아이스크림, 음료, 소세지 및 쵸코렛 등의 음식물에 함께 배합함으로써, 청소년, 성인 및 노인층의 광범위한 계층까지 언제 어디서나 늘 간편하게 섭취할 수 있어서 지속적인 음용효과를 기대할 수 있는 암예방 효과를 갖는 황금 추출물이 배합된 음식물에 관한 것이다.The present invention relates to a method of using the gold extract as an activity inducer of quinone reductase (Finone reductase) and to a food containing the same, more specifically, the gold extract induces the activity of quinone reductase to prevent cancer By combining it with foods such as chewing gum, candy, biscuits, ice cream, beverages, sausages and chocolates, it can be easily consumed anytime, anywhere to a wide range of teenagers, adults and the elderly, and expect continuous drinking effects. It relates to a food compound containing a golden extract having a cancer prevention effect.

암은 우리나라 사람의 사망원인 중 하나로 발병사실을 알고난 뒤 1년 이내에 사망하는 경우가 전체의 51.1%이며, 치료 실적은 꾸준하게 향상되어 왔지만, 의학자들은 20세기말까지 완치율이 50%를 넘지 못할 것이라고 보고 있으며, 해마다 세계적으로 8백만명의 환자가 발생되고 있으며, 이 중 5백만명이 죽는 인류 최악의 병이다.Cancer is one of the causes of death in Korea, and 51.1% of all cases die within a year after knowing the onset of disease, and the treatment results have been steadily improving, but medical researchers report that the cure rate will not exceed 50% by the end of the 20th century. Each year, there are 8 million cases worldwide, of which 5 million are the worst of all.

이러한 암의 유발인자인 발암물질로는 음식물, 흡연, 자외선, 화학물질, 기타 환경인자들이 있으며, 인간은 자의 또는 타의에 의하여 이러한 발암물질에 노출될 수밖에 없는 것이 현실이다.Carcinogens that cause such cancers include food, smoking, ultraviolet rays, chemicals, and other environmental factors, and the reality is that humans have to be exposed to these carcinogens by will or by other means.

따라서, 암 예방물질의 개발이 절실히 요구되고 있는데, 이러한 암 예방물질의 개발은 암 뿐만 아니라, 모든 질병을 억제하거나 치료하는데 매우 유용하게 이용될 수 있다. 이런 이유로, 암 예방물질의 개발이 암 연구의 새로운 방향으로 인식되고 관심이 집중됨에 따라, 암 예방물질 소재의 개발이 실제 의약분야 뿐만 아니라, 식품 화학분야에서도 활발하여 천연물 소재들에 대한 연구가 적극적으로 이루어지고 있는 실정이며, 또한 식품분야에도 실제 도입되어 오고 있다.Therefore, there is an urgent need for the development of cancer prevention substances, and the development of such cancer prevention substances can be very useful for inhibiting or treating all diseases as well as cancer. For this reason, as the development of cancer prevention substances is recognized as a new direction of cancer research and attention is focused, the development of cancer prevention substance materials is active not only in the real medicine field, but also in the food chemical field, so that research on natural product materials is active. In fact, it is also being introduced into the food sector.

그 결과, 미생물이나 동물세포 등을 이용한 많은 분석계가 확립되어 새로운 암 예방물질의 탐색연구에 활용되고 있으며, 활성성분의 순수분리 및 작용기작의분자 생물학적 연구 또한 활발히 진행되고 있다.As a result, many analytical systems using microorganisms and animal cells have been established and utilized for the search for new cancer prevention substances, and active biological studies of pure separation of active ingredients and molecular mechanisms of action are also in progress.

여러가지 종양의 초기 발단은 발암 물질, 변이원성 물질, 활성산소종에 의하여 DNA에 손상을 주게 됨으로서 일어나는데, 포유류의 세포는 그러한 손상에 대해 보호작용을 가지는 복합적이고 정교한 작용기작을 지니고 있다. 즉, 전자 친화성을 가진 발암물질들이 무독화 효소들에 의해 불활성화되어 체외로 배출되면 암으로 진행이 되지 않지만, DNA와 복합체(adduct)를 형성하여 돌연변이 또는 전환(transformation) 과정을 거치면 암으로 진행되게 된다.Early onset of various tumors is caused by damaging DNA by carcinogens, mutagenic substances, and reactive oxygen species, and mammalian cells have complex and sophisticated mechanisms of action that protect against such damage. In other words, when carcinogens with electron affinity are inactivated by detoxifying enzymes and released into the body, they do not progress to cancer, but they form a complex with DNA and undergo a mutation or transformation process. It is going to proceed.

특히, 상기한 무독화 효소들 중에서도 제 2상계(Phase Ⅱ) 무독화 효소는 각종 암세포에 대한 특이적인 세포독성을 나타내어 항암기능을 갖는 등의 발암 물질, 변이원성 물질, 활성산소종에 의한 DNA에 손상으로부터의 보호작용을 갖는다고 알려져 있다. 이러한 제 2상계(Phase Ⅱ) 무독화 효소로는 글루타치온 설퍼 트란스퍼라제(glutathione sulfur transferase, GST), NAD(P)H : 퀴논 리덕타아제(quinone reductase, QR), 에폭사이드 하이드로라제(epoxide hydrolase), 글루쿠로노실 트란스퍼라아제(glucuronosyltransferase), 알데하이드 리덕타아제(aldehyde reductase) 등이 있다.In particular, among the above detoxification enzymes, Phase II detoxification enzyme exhibits specific cytotoxicity against various cancer cells and thus damages DNA caused by carcinogens, mutagenic substances, and reactive oxygen species such as having anticancer function. It is known to have a protective action against. Such Phase II detoxification enzymes include glutathione sulfur transferase (GST), NAD (P) H: quinone reductase (QR), and epoxide hydrolase. ), Glucuronosyltransferase, aldehyde reductase and the like.

상기 제 2상계(Phase Ⅱ) 무독화 효소 중에서, 퀴논 리덕타아제(Quinone reductase, E.C. 1.6.99.2)는 돌연변이 또는 발암물질 등에 의한 DNA와의 상호작용을 차단하는 효소이며, NAD(P)H를 이용하여 퀴논(Quinone)류의 환원을 촉매하는 플라보프로테인(flavoprotein)이다. 또한, 분자량은 54,000 daltons이고 동일한 구조가 2개 결합된 것(homodimer)으로 그 각각은 273개의 아미노산으로 구성되어있으며, 활성부위에는 플라빈 아데닌 디뉴클레오타이드(flavin adenine dinucleotide, FAD)를 함유하고 있는 플라보프로테인(flavoprotein)으로, 일명 메나디온 리덕타아제(menadione reductase), 비타민 K 리덕타아제(vitamin K reductase), DT-다이아포라아제(DT-diaphorase)로 명명된다.Of the Phase II detoxification enzymes, quinone reductase (EC 1.6.99.2) is an enzyme that blocks interaction with DNA by mutations or carcinogens, and uses NAD (P) H. It is a flavoprotein that catalyzes the reduction of quinones. In addition, the molecular weight is 54,000 daltons, the same structure of two (homodimer) each composed of 273 amino acids, the active site flavin containing flavin adenine dinucleotide (FAD) Boproprotein (flavoprotein), also known as menadione reductase (menadione reductase), vitamin K reductase (vitamin K reductase), DT-diaphorase (DT-diaphorase).

이러한 퀴논 리덕타아제는 여러 가지 특징들을 갖고 있는데, 첫째, NAD(P)H를 전자 공여체로 이용하고, 둘째, 2개의 전자를 이동시켜 세미퀴논(semiquinone)을 형성하지 않으며, 셋째, 디쿠마놀(dicoumarol)과 같은 항혈액응고제에 의해 강한 저해를 받으며, 넷째, 많은 세포와 조직에서 여러 가지 외부물질들에 의해 유도되는 것이다. 특히, 이러한 퀴논 리덕타아제는 퀴논(quinone)류 자체에 대한 보호효과가 있음은 물론, 다른 암예방 효소계와 공통적으로 유도되며 항암작용이 있는 많은 화합물에 의해 유도되는 특징으로 인하여 제 2상계(Phase Ⅱ) 무독화효소중 암 예방물질 탐색의 지표가 되는 대표적인 효소로 선정될 수 있는 것이다[Lind, C., Vady, H. and Ernster, L. 1978, Arch. Biochem Biophys. 190 : 97-108; Wefers, H., Komai, T., Talalay, P. and Sies, H. 1984. FEBS Lett. 169:63-66].These quinone reductases have a number of characteristics, firstly, using NAD (P) H as an electron donor, and secondly, not shifting two electrons to form a semiquinone, and thirdly, dicumanol It is strongly inhibited by anticoagulants such as dicoumarol. Fourth, it is induced by various foreign substances in many cells and tissues. In particular, these quinone reductases have a protective effect on quinones themselves, and are commonly induced with other cancer prevention enzymes and are induced by many compounds with anticancer activity. Ⅱ) Among the detoxification enzymes, it can be selected as a representative enzyme for the search for cancer prevention substance [Lind, C., Vady, H. and Ernster, L. 1978, Arch. Biochem Biophys. 190: 97-108; Wefers, H., Komai, T., Talalay, P. and Sies, H. 1984. FEBS Lett. 169: 63-66.

한편, 퀴논 리덕타아제(Quinone reductase)의 측정을 보다 신속, 간단하고 정확하게 하기 위해 여러 종류의 동물세포를 이용할 수 있으며, 본 발명에서는 생쥐의 간세포주(Hepa 1c1c7 murine hepatoma cell line)를 도입하였다. 이러한 세포주에 의해 퀴논 리덕타아제(Quinone reductase) 유도활성이 나타나는 물질들로는 부틸 하이드록시 아니솔(BHA), 부틸 하이드록시 톨루엔(BHT), 터셔리-부틸 하이드록시 퀴논(t-BHQ)을 포함하는 페놀(phenol)성 항산화물질; 1,1'-아조나프탈렌(1,1'-azonaphthalene)과 수단(sudan) I, Ⅲ의 친유성 아조(azo) 염색류; 폴리사이클릭 아로마틱 카아본(polycyclic aromatic carbon); 쿠마린(coumarin)과 락톤(lactone)류; 플라보노이드(flavonoids)류; 벤질이소티오시아네이트(benzylisothiocyanate), 디티올티온(dithiolthiones)과 디티오카아바메이트(dithiocarbamate)를 포함하는 황화합물 등이 있다. 이 중에서도 십자화과 식물(브로콜리, 양배추, 케일, 콜리플라워 등), 릴리아세(liliaceae)과 식물(양파, 마늘)과 바시니움(Vaccinium)속 식물[로우부쉬(lowbush), 블루베리(blue-berry), 빌베리(bilberry), 크랜베리(cranberry), 린곤베리(lingonberry)]에서 퀴논 리덕타아제(Quinone reductase) 유도활성이 강하게 나타난다고 보고되어 있다. 상기한 것들 중에서도 특히, 현재까지 밝혀진 것 중 가장 활발한 연구가 진행중이고 강력한 유도제로는 브로콜리(Brassica oleraceae)의 활성물질인 설포라판(sulforaphane, (CH3-S(O)-(CH2)4-N=C=S)으로서 이소티오시아네이트(isothiocyanate)의 일종이며 유도기작 등 많은 연구가 되어있는 실정이다[Gerhauser, C., You, M., Liu, J., Moriarty, R.M., Hawthorne, M., Mehts, R.G., Moon, R.C. and Pezzuto, J.M. 1997. Cancer Research 57 : 272-278; Posner, G.H., Cho, C.G., Green, G.V., Zhangg, Y. and Talalay, P. 1994, J. Med. chem. 37:170-176].Meanwhile, various kinds of animal cells can be used to more quickly, simply and accurately measure the quinone reductase, and in the present invention, a mouse liver cell line (Hepa 1c1c7 murine hepatoma cell line) has been introduced. Substances exhibiting quinone reductase-inducing activity by these cell lines include butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tertiary-butyl hydroxy quinone (t-BHQ). Phenolic antioxidants; Lipophilic azo dyes of 1,1'-azonaphthalene and sudan I, III; Polycyclic aromatic carbons; Coumarin and lactones; Flavonoids; Benzyl isothiocyanate, sulfur compounds including dithiolthiones and dithiocarbamate. Among them, cruciferous plants (broccoli, cabbage, kale, cauliflower, etc.), liliaceae plants (onions, garlic) and Vaccinium plants (lowbush, blue-berry) ), Bilberry (cranberry), cranberry (lingonberry)] is reported to have a strong quinone reductase (kinin reductase) induction activity. Among the above, in particular, the most active research to date and the strongest inducing agent is sulfoaphane (CH 3 -S (O)-(CH 2 ) 4 -N, an active substance of Brassica oleraceae ). = C = S) is a kind of isothiocyanate and has been studied a lot of induction mechanisms [Gerhauser, C., You, M., Liu, J., Moriarty, RM, Hawthorne, M. , Mehts, RG, Moon, RC and Pezzuto, JM 1997. Cancer Research 57: 272-278; Posner, GH, Cho, CG, Green, GV, Zhangg, Y. and Talalay, P. 1994, J. Med. Chem 37: 170-176.

본 발명자들은 이러한 추세에 발 맞추어 연구 노력한 결과, 황금 추출물이기존의 퀴논 리덕타아제의 활성 유도물질들과 비교해서 보다 높거나 동등한 정도의 퀴논 리덕타아제(Quinone reductase)의 활성을 유도하여 탁월한 암 예방효과를 가짐을 확인하였다.The present inventors have made efforts to keep pace with these trends, and as a result, the gold extract extracts a higher or equivalent amount of quinone reductase activity compared to the active inducers of the existing quinone reductase. It was confirmed that it has a preventive effect.

황금(Scutellaria baicalensisGeorge)은 꿀풀과(Labiatae)에 속하는 다년생 초본이며 주원산지는 한국과 중국을 비롯한 동북 아시아로서 한국 전역과 양자강 이북의 중국 및 시베리아 등 동북 아시아에 자생 또는 재배되고 있다. 특히, 중국에서는 중북부에서 동북부에 걸쳐 다양한 스쿠텔라리아(Scutellaria)속 식물이 분포되어 자생하고 있다. 황금은 일명 속썩은풀이라고도 하며 다른 이름으로는 부장(신농본초경초), 내허, 공장, 경금, 황문(명의별록), 인두(오보본초) 등으로 불리어진다. 높이는 20 ∼ 60 ㎝ 정도이고 7월에서 9월 사이에 자색의 꽃을 개화하는 단일성 식물로서 우리나라 전역에서 재배가 가능하며 용도는 주로 약용으로 사용되나 관상용 또는 식용으로 이용되기도 한다. Scutellaria baicalensis George is a perennial herb belonging to the labiatae , and its main origin is Northeast Asia including Korea and China, and is grown or grown in Northeast Asia including China and Siberia in the north of Yangtze River. In particular, in China, a variety of Scutellaria ( Scutellaria ) plants are distributed in the mid-North to the north-east. Gold is also known as deciduous grass, and other names are general managers (new agricultural plants), inner gardens, factories, gold plants, yellow gates (namebooks), and pharynxes (obovones). It is 20 ~ 60 ㎝ high and is a single plant that blooms purple flowers between July and September. It can be cultivated throughout Korea. It is mainly used for medicinal purposes, but also for ornamental or edible use.

본 발명에서 사용한 황금의 뿌리부분의 모양은 방추상 또는 반관상을 이루며 길이는 8 ∼ 20 ㎝, 지름은 5 ∼ 20 ㎜이다. 바깥면은 모양이 조잡하고 가로주름이 있으며, 여러 곳에 측근이 붙었던 자국이 있다. 약용으로는 주로 구근을 이용하며 소염성 해열, 진통, 지사, 동맥경화성 고혈압 등의 치료에 이용된다. 또한, 향약대사전에는 '실화를 사하고 습은열을 제거하며 지혈, 안태의 효능이 있다' 고 기록되어 있다.The root of the golden root used in the present invention is fusiform or semi-tubular, and has a length of 8 to 20 cm and a diameter of 5 to 20 mm. The outer surface is coarse in shape and has a horizontal wrinkle, and the marks are attached to the entourage in various places. It is mainly used as a medicine and is used for the treatment of anti-inflammatory antipyretic, analgesic, branch, and atherosclerosis hypertension. In addition, it is recorded in the dictionary of medicinal herbs, 'the death of the true story, the elimination of the moist heat, hemostasis, has the effect of anxiety'.

이러한 황금의 대표적인 성분은 플라보노이드(flavonoids)로 밝혀져 있으며, 식물계에 현재까지 약 4,000여종의 플라보노이드(flavonoid) 화합물이 알려져 있다. 황금의 성분에 대한 연구는 1970년대 이후 과학적인 분석기기를 이용하여 본격적으로 시작되었으며, 그 후 부삼 등(부삼 의, 궁일론기범, 정본길융, 목진치구. 1984.Scutellaria속식물성분연구(제 3 보)(황금의 후라보노이도 성분について その3. 약학잡지. 104: 524 ∼ 528)에 의해 집중적인 연구가 수행되어 지금까지 바이칼린(baicalin), 바이칼레인(baicalein), 오고닌-7-O-글루쿠로나이드(Wogonin-7-O-glucuronide), 오고닌(Wogonin), 오록실린 A-O-글루쿠로나이드(Oroxylin A-7-O-glucuronide), 오록실린 A(Oroxylin A), 스쿨캅플라본 I(Skullcapflavone I), 디하이드로오록실린 A(Dihydrooroxylin A), 바이칼레인-7-O-글루코사이드(Baicalein-7-O-glucoside) 등 약 60여종의 플라보노이드(flavonoid) 화합물들의 구조가 밝혀져 있다. 이들 성분은 식물중에 너무 많이 함유되어 있기 때문에 오히려 주목을 끌지 못하였으나, 최근 이에 대한 다양한 약리적 활성이 보고되면서부터 황금의 식물세포 배양 등을 통한 보다 많은 양의 플라보노이드(flavonoids)를 생산하는 연구가 보고되어있다[Seo, W. T., Park, Y. H. and Choe, T. B. 1993. Identification and production of flavonoids in a cell suspension culture of Schutellaria baicalensis G. Plant Cell Reports. 12: 414 ∼ 417].The representative component of the gold is known as flavonoids (flavonoids), and about 4,000 kinds of flavonoid compounds (flavonoid) compounds are known in the plant kingdom to date. Since the 1970s, studies on the composition of gold began in earnest using scientific analyzers. Since then, the ginseng, etc. (Bussam, Gillonil Bum, Jung Bon Gil-lung, Mokjin Jig. 1984. Research on plant composition of Scutellaria (3rd) (Investigations have been carried out by Golden Flavorinoid Ingredients. Pharmacy Magazine 104: 524-528). So far, baicalin, baicalein, and ogonin-7-O -Glucuronide (Wogonin-7-O-glucuronide), Ogonin (Wogonin), Oroxylin AO-Glucuronide (Oroxylin A-7-O-glucuronide), Oroxylin A (Oroxylin A), Schoolcap About 60 flavonoid compounds such as flavone I (Skullcapflavone I), Dihydrooroxylin A (Baicalein-7-O-glucoside) and the like have been identified. These ingredients were not so noticeable because they were so much in the plant. In recent years, various pharmacological activities have been reported, and more studies have been reported on the production of higher amounts of flavonoids through plant culture of gold [Seo, WT, Park, YH and Choe, TB 1993. and production of flavonoids in a cell suspension culture of Schutellaria baicalensis G. Plant Cell Reports.12: 414-417.

또한, 황금의 알콜장해 예방 및 치료제 조성물이 [대한민국특허공개 제96-40370호]에 공지되어 있고, 황금의 후라보노이드 성분으로 된 백내장 치료제가 [대한민국특허공개 제96-3725호]에 공지되어 있으며, 황금 추출물을 유효성분으로 하는 치주질환 예방 및 치료제 조성물이 [대한민국특허공개 제94-11006호]에 제안되어 있다. 그러나, 상기한 기술은 아직 범용화되지는 못하고 있는 실정이다.In addition, a golden alcohol disorder prevention and treatment composition is known in [Korean Patent Publication No. 96-40370], and a cataract treatment agent of a golden flavonoid component is known in [Korean Patent Publication No. 96-3725], A periodontal disease prevention and treatment composition comprising the golden extract as an active ingredient is proposed in [Korean Patent Publication No. 94-11006]. However, the above described technology is not yet widely used.

특히, 오늘날 암예방 효능을 나타내는 천연물질에 대한 많은 연구에도 불구하고, 본 발명에서 나타낸 바와 같이 황금 추출물이 암 예방효과를 갖는다는 것에 대한 연구는 없었으며, 또한, 이를 음료, 츄잉껌, 캔디, 비스켓 및 아이스크림 등의 음식물에 적용한 예 또한 없었다.In particular, despite many studies of natural substances that exhibit cancer prevention effects today, there has been no research showing that the golden extract has a cancer prevention effect as shown in the present invention, and it is also used as a beverage, chewing gum, candy, biscuits. And no application to foods such as ice cream.

본 발명자들은 황금 추출물이 퀴논 리덕타아제(Quinone reductase)의 활성을 유도하여 암 예방효과를 가짐을 확인하고, 이를 음식물에 적용함으로써, 본 발명을 완성하였다.The inventors have confirmed that the golden extract has the effect of preventing cancer by inducing the activity of quinone reductase (Quinone reductase), and completed the present invention by applying it to food.

따라서, 본 발명은 종래에 생약재로서 황금원료 및 그 추출물을 제한적으로 사용하던 기존의 방법을 탈피하여 황금 추출물을 음식물에 첨가 배합함으로써, 황금 자체가 지니고 있는 다양한 약리적 활성 즉, 소염성 해열, 진통, 지사, 동맥경화성 고혈압과 백내장에 대한 치료효과 및 알콜장해 예방효과를 충분히 살릴 뿐만 아니라, 퀴논 리덕타제(Quinone reductase) 활성을 유도함으로써 암 예방효과를 도모할 수 있는 황금 추출물을 함유하는 음식물을 제공하는데 그 목적이 있다.Therefore, the present invention by adding and blending the golden extract to food to avoid the conventional method of using the golden raw material and its extract as a conventional herbal medicine, the various pharmacological activity of the golden itself, namely anti-inflammatory antipyretic, analgesic, It provides foods containing golden extracts that can prevent cancers by inducing quinone reductase activity, as well as treating the effects of branch offices, atherosclerosis hypertension and cataracts and preventing alcohol disorders. Its purpose is.

도 1은 생쥐의 간세포(mouse, hepatoma cell ; Hepa 1c1c7 cell)를 이용하여 황금 추출물 25 ∼ 100 ㎍/㎖ 농도에서 퀴논 리덕타제(Quinone reductase) 유도효과를 나타낸 것이고,Figure 1 shows the effect of inducing quinone reductase (Quinone reductase) at a concentration of 25 ~ 100 ㎍ / ㎖ of gold extract using mouse hepatocytes (mouse, hepatoma cells; Hepa 1c1c7 cells),

도 2는 스프로그 도올리(Sprague-Dawley)계 쥐에게 황금 추출물 200 ∼ 1,000 ㎎/㎏ 농도로 투여한 후, 퀴논 리덕타제(Quinone reductase) 유도효과를 나타낸 것이다.Figure 2 shows the effect of inducing quinone reductase after administration of Sprague-Dawley rats at a concentration of 200 ~ 1,000 mg / kg golden extract.

본 발명은 황금 추출물을 퀴논 리덕타아제(quinone reductase)에 대한 활성 유도물질로 사용하는 방법을 그 특징으로 한다.The present invention is characterized by a method of using the gold extract as an activity inducer for quinone reductase.

또한, 본 발명은 황금 추출물이 퀴논 리덕타아제(quinone reductase)에 대한활성 유도물질로 전체 조성에 대해 0.1 ∼ 1.0 중량% 함유된 음식물에 관한 것을 포함한다.In addition, the present invention includes a food extract containing 0.1 to 1.0% by weight of the total extract as an activity inducing substance for quinone reductase (quinone reductase).

이와같은 본 발명을 더욱 상세하게 설명하면 다음과 같다.The present invention will be described in more detail as follows.

본 발명은 황금 추출물을 퀴논 리덕타아제(Quinone reductase)의 활성 유도물질로 사용하여 암예방 효과를 갖도록 한 황금 추출물의 새로운 용도에 관한 것이다.The present invention relates to a new use of the golden extract to have a cancer prevention effect by using the golden extract as an activity inducer of quinone reductase.

일반적으로 황금 추출물을 얻는 방법으로는 에탄올 등을 이용한 용매추출이나 단수 열수추출 등의 방법이 있는데, 본 발명에서는 에탄올을 용매로하고 초음파를 사용하여 추출하는 방법을 사용하는 바, 이를 더욱 상세히 하고자 한다.In general, a method of obtaining a golden extract may include a solvent extraction using ethanol or the like, or a single hot water extraction. In the present invention, ethanol is used as a solvent and extracted using ultrasonic waves. .

먼저, 시료인 황금에 에탄올을 넣고 초음파로 20 ∼ 40분 동안 1 ∼ 4회 반복 추출한 다음, 도요여지(Toyo filter) No.2로 여액을 얻어 감압농축기(Rotary vacuum evaporator)로 45 ∼ 55℃에서 감압농축시키고 농축물은 동결건조하여 노란색의 황금 건조분말을 얻고, 이를 -70 ℃의 온도에서 보관하는 방법을 사용하였다. 이때, 상기 감압농축시 온도를 55℃를 초과할 경우에는 활성물질 등에 손상이 우려된다.First, ethanol was added to gold, a sample, and extracted repeatedly by ultrasonic wave for 1 to 4 times for 20 to 40 minutes. Then, the filtrate was obtained using Toyo filter No. 2 at 45 to 55 ° C. with a rotary vacuum evaporator. Concentrated under reduced pressure and the concentrate was lyophilized to obtain a yellow golden dry powder, which was stored at a temperature of -70 ℃. At this time, if the temperature under reduced pressure concentration is more than 55 ℃ damage to the active material and the like.

여기서, 상기한 바와 같이 황금 원료로부터 황금 추출물을 얻는데 있어서, 에탄올을 사용하므로 단순히 물을 사용할 경우에 비하여 극성이 낮은 물질까지 추출이 가능한 장점을 얻을 수 있으며, 초음파를 사용하여서는 방치 또는 진탕추출보다 더욱 효과적으로 추출이 가능한 장점이 있다.Here, as described above, in obtaining the golden extract from the golden raw material, since ethanol is used, it is possible to obtain the advantage that it is possible to extract a substance having a low polarity as compared to simply using water, and by using ultrasonic waves, it is more effective than the extraction or shaking extraction There is an advantage that can be extracted effectively.

상기와 같은 제조방법으로 제조된 황금 추출물에 대하여 퀴논리덕타제(Quinone reductase) 유도 효과를 측정한 결과, 암예방 효과가 상당히 우수함을 확인하고, 이를 츄잉껌, 캔디, 비스켓, 아이스크림, 음료, 소세지 및 쵸코렛 등에 적용할 수 있는 바, 이렇게 음식물에 함께 배합함으로써, 청소년, 성인 및 노인층의 광범위한 계층까지 언제 어디서나 늘 간편하게 섭취할 수 있어서 지속적인 음용효과를 기대할 수 있는 것이다.As a result of measuring the quinone reductase induction effect on the golden extract prepared by the above manufacturing method, it was confirmed that the cancer prevention effect is quite excellent, and chewing gum, candy, biscuits, ice cream, drinks, sausage and It can be applied to chocolate bar, etc. By combining it with food, it can be easily consumed anytime, anywhere up to a wide range of adolescents, adults and the elderly can be expected continuous drinking effect.

본 발명에서와 같이, 황금 추출물을 음식물에 적용하는 경우에는 전체 조성물에 대하여 황금 추출물을 필수적으로 0.1 ∼ 1.0 중량% 함유하도록 사용하는 것이 바람직하다. 만일, 그 함량을 0.1 중량% 미만으로 하면 본 발명이 목적으로 하는 효과를 얻을 수 없어 바람직하지 않고, 반면에 상기 범위를 초과하여 과량으로 첨가되면, 비경제적이면서 완성제품의 맛, 색깔에 영향을 미칠 수 있기 때문에 바람직하지 않다.As in the present invention, when the golden extract is applied to food, it is preferable to use the golden extract in an amount of 0.1 to 1.0 wt% based on the total composition. If the content is less than 0.1% by weight, the present invention may not achieve the desired effect, and if it is added in excess of the above range, it may be uneconomical and affect the taste and color of the finished product. It is not desirable because it can be crazy.

이하, 본 발명을 실시예에 의거 더욱 상세히 설명하겠는 바, 본 발명이 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited by Examples.

비교 실험예 : 천연물 자원으로부터 퀴논 리덕타아제 유도물질 탐색Comparative Experimental Example: Screening of Quinone Reductase Inducer from Natural Products

퀴논 리덕타아제의 활성유도활성이 가장 강한 유도물질을 선정하기 위해서 퀴논 리덕타아제의 활성유도물질로 알려진 약용식물 72종, 곡류 10종, 야채 및 과일류 66종, 향신료 및 기타 27종의 에탄올 추출물과 청국장으로부터 분리한 미생물의 배양 상등액 43종 등 총 218종을 대상으로 Hepa 1clc7 cell culture system에서 퀴논 리덕타아제 활성에 미치는 영향을 조사하였고, 그 결과를 다음 표 1a ∼ 1j에나타내었다.To select the most inducible inducers of quinone reductase, 72 medicinal plants, 10 cereals, 66 vegetables and fruits, spices and 27 other ethanol known as quinone reductase active inducers A total of 218 species, including 43 supernatants of the microorganisms extracted from the extract and Chunggukjang, were investigated for their effects on quinone reductase activity in the Hepa 1clc7 cell culture system. The results are shown in Tables 1a to 1j below.

상기 표 1a ∼ 1j에 나타난 바와 같이 천황련, 딜(dill), 향나무, 주목나무, 황금, 소나무, 홍화, 상수리, 밤나무, 졸참나무, 고들빼기, 카카오콩 껍질(cacao bean husk), 쑥갓, 브로콜리, 샐러리, 마늘줄기, 수박, 파인애플, 데라웨어, 코리안더, 아카리커스(agaricus), c18-4 및 c19-2 등 총 23종에서 대조군에 비해 50% 이상의 유도활성을 나타냈으며, 이중 퀴논 레덕타제 유도활성이 가장 강한 황금 추출물을 최종적으로 선정하였다.As shown in Tables 1a to 1j, cheonnyeon, dill, juniper, yew, golden, pine, safflower, oak, chestnut, prunus oak, walrus, cacao bean husk, cucurbita, broccoli, A total of 23 species, including celery, garlic stem, watermelon, pineapple, deraware, coriander, acaricus, c18-4 and c19-2, showed more than 50% induction activity compared to the control group, and quinone reductase induction activity. This strongest golden extract was finally selected.

참고예 : 동물세포주 배양 및 실험동물 사육Reference Example: Animal cell line culture and experimental animal breeding

본 발명에 사용된 동물세포주인 생쥐(mouse)유래의 간세포(Hepa 1c1c7 cell line)는 미국의 분양기관(The American Type Culture Collection, ATCC CRL 2026)으로부터 구입하였으며, 2 mM 글루타민(glutamine), 100 U/㎖ 페니실린 G(penicillin G), 100 ㎍/㎖ 스트렙토마이신(streptomycin), 10% 피탈 보바인 시럼(fetal bovine serum) 등을 포함하는 알파-엠이엠(α-MEM, minimum essential medium alpha modification) 배지를 첨가하여 37℃의 5% CO2/95% air 환경의 CO2배양기(incubator)내에서 계대배양하면서 실험에 이용하였다.Mouse-derived hepatocytes (Hepa 1c1c7 cell line) used in the present invention were purchased from the American Type Culture Collection (ATCC CRL 2026), 2 mM glutamine (glutamine), 100 U Minimum essential medium alpha modification (α-MEM) medium containing / ml penicillin G, 100 μg / ml streptomycin, 10% petal bovine serum, and the like Was used in the experiment while subcultured in a CO 2 incubator at 37 ℃ 5% CO 2 /95% air environment.

한편, 실험동물은 체중 85g 내외의 3주령 스프로그-돌리(Sprague-Dawley)계 흰쥐 암컷을 국립보건원의 동물사육실로부터 분양 받아 사용하였다. 동물사육 환경은 12시간 간격의 인공조명(AM : 08 ∼ PM : 08), 조도 300 ∼ 500 lux, 온도 23±1℃, 배기 10 ∼ 18 회/h 의 조건으로 유지하였으며, 고형사료(삼양사료)와 식수는 자유롭게 섭취하도록 하였다.On the other hand, the experimental animals were used to receive a three-week-old Sprague-Dawley rat females of about 85g body weight from the animal nursery of the National Institutes of Health. The animal breeding environment was maintained under the conditions of artificial lighting (AM: 08-PM: 08), illumination intensity 300-500 lux, temperature 23 ± 1 ° C, exhaust 10-18 times / h at 12 hour intervals, and solid feed (Samyang feed). ) And drinking water freely.

실시예 : 황금 추출물의 분리Example: Isolation of Golden Extract

본 발명에서 사용한 공시재료는 경동시장에서 국내산 황금을 구입하여 이물질을 제거하고 세절하여 사용하였으며, 추출용 용매는 1급 시약을 사용하였고, 나머지 시약은 미국 시그마(Sigma)사 제품 및 특급시약을 이용하였다.The disclosure material used in the present invention was purchased by domestic gold in the Gyeongdong market to remove foreign matter and finely used, the extraction solvent was used as a first-class reagent, the remaining reagents are US Sigma (Sigma) products and special reagents It was.

시료인 황금 500g에 에탄올 5ℓ를 넣고 초음파(Nihonseiki kaisha, Model No. NS-300)로 30분간 3회 반복 추출한 다음, 도요여지(Toyo filter) No.2로 여액을 얻어 감압농축기(Rotary vacuum evaporator)로 50℃에서 감압농축시키고 농축물은 동결건조 하여 노란색의 황금 건조분말을 얻었다. 이후 시료를 -70 ℃에서 보관하면서 사용하였다.5 g of ethanol was added to 500 g of gold, a sample, and extracted three times for 30 minutes using ultrasonic waves (Nihonseiki kaisha, Model No. NS-300), and the filtrate was obtained using a Toyo filter No. 2 to obtain a vacuum vacuum evaporator. The mixture was concentrated under reduced pressure at 50 ° C. and the concentrate was lyophilized to obtain a yellow golden dry powder. The sample was then used while stored at -70 ° C.

실험예 1 : 생쥐의 간세포를 이용한 퀴논 리덕타아제의 저해활성 측정Experimental Example 1 Measurement of Inhibitory Activity of Quinone Reductase Using Mouse Hepatocytes

퀴논 리덕타아제(Quinone reductase, E.C. 1.6.99.2) 활성저해 측정은 프로카스카[Prochaska H. J. and Santamaria A. B. 1988. Anal. Biochem. 169: 328∼336, 1988] 등이 제시한 방법을 일부 변형하여 측정하였다.Quinone reductase (E.C. 1.6.99.2) deactivation assay was measured by Prochaska H. J. and Santamaria A. B. 1988. Anal. Biochem. 169: 328-336, 1988] and some modifications of the method presented.

우선, 24 웰 플레이트(well plate)의 각 웰(well)에 동일한 수(1.0 × 104cells/㎖)의 생쥐의 간세포(Hepa 1c1c7 cells)를 분주하고, 24시간 전 배양한 다음에 상기 실시예를 통해 제조된 황금 추출물을 첨가한 후, 다시 24시간 동안 배양한 다음, 배지를 제거하였다. 그 다음에, 각 웰에 250 ㎕의 라이시스 완충액[lysis buffer(10 mM Tris-Cl, pH 8.0, 140 mM NaCl, 15 mM MgCl2, 0.5% NP-40)]을 첨가한 후, 25℃의 온도조건하에서 10분간 서서히 흔들어주면서 세포를 용해시켰다. 여기에, 1 ㎖의 효소용액을 첨가하여, 5분간 반응시킨 후, 250 ㎕의 반응정지 용액[0.3 mM 디쿠마놀(dicoumarol), 0.5% 피리딘(pyridine), 5 mM 포타시움 포스페이트(potassium phosphate, pH 7.4)]로 효소반응을 정지시킨 다음, 610 nm에서의 흡광도를 측정하였다. 또한, 단백질량은 동일한 세트(set)의 웰 플레이트(well plate)에 대한 크리스탈 바이올렛(crystal violet) 염색방법으로 정량하였다. 이때, 상기 효소용액은 반응액의 최종농도가 10 mM인 트리스 완충액(Tris-Cl, pH 7.4), 0.5 ㎎/㎖ 보바인 시럼 알부민(BSA), 0.008 % 트윈-20(Tween-20), 40 μM 플라빈 아데닌 디뉴클레오타이드(FAD), 0.8 mM 글루코즈 6-포스페이트(glucose 6-phosphate), 2 U/㎖ 글루코즈 6-포스페이트 디하드로게나아제(glucose 6-phosphate dehydrogenase), 25μM 니코틴아마이드 아데닌 디뉴클레오타이드(NADP), 40μg/㎖ 3-(4,5-디메틸- 티아조-2-일)-2,5-디페닐테트라졸리움브로마이드[3-(4,5-dimethyl-thiazo-2-yl)-2,5-diphenyltetrazoliumbromide(MTT)] 및 1 mM 메나디온(menadione)이 함께 함유되어 있는 것을 사용하였다.First, the same number (1.0 × 10 4 cells / ml) of mouse hepatocytes (Hepa 1c1c7 cells) were dispensed into each well of a 24 well plate, and cultured 24 hours before. After adding the golden extract prepared through, incubated again for 24 hours, and then the medium was removed. Next, 250 μl of Lysis buffer (lysis buffer (10 mM Tris-Cl, pH 8.0, 140 mM NaCl, 15 mM MgCl 2 , 0.5% NP-40)) was added to each well, followed by Cells were lysed by shaking slowly for 10 minutes under temperature conditions. To this, 1 ml of enzyme solution was added and allowed to react for 5 minutes, followed by 250 µl of reaction stopping solution [0.3 mM dicoumarol, 0.5% pyridine, 5 mM potassium phosphate, pH 7.4)], and then the absorbance at 610 nm was measured. In addition, the amount of protein was quantified by crystal violet staining on the same set of well plates. At this time, the enzyme solution is the final concentration of the reaction solution 10 mM Tris buffer (Tris-Cl, pH 7.4), 0.5 mg / ml bovine serum albumin (BSA), 0.008% Tween-20, 40 μM flavin adenine dinucleotide (FAD), 0.8 mM glucose 6-phosphate, 2 U / ml glucose 6-phosphate dehydrogenase, 25 μM nicotinamide adenine dinucleotide (NADP), 40 μg / ml 3- (4,5-dimethyl-thiazo-2-yl) -2,5-diphenyltetrazolium bromide [3- (4,5-dimethyl-thiazo-2-yl)- 2,5-diphenyltetrazoliumbromide (MTT)] and 1 mM menadione were used together.

그리고, 다음 수학식 1을 사용하여 퀴논 리덕타제 활성도를 계산하였고, 그 결과를 첨부도면 도 1에 나타내었다. 이때, 대조구로는 황금추출물을 녹인 용제를 사용하였다.Then, the quinone reductase activity was calculated using Equation 1, and the results are shown in the accompanying drawings. In this case, a solvent in which the golden extract was dissolved was used as a control.

첨부도면 도 1에 의하면, 노란색 황금 추출물을 25, 50, 75, 100 ㎍/㎖ 농도로 생쥐의 간세포(Hepa 1c1c7 cell)에 처리한 다음, 퀴논 리덕타아제(quinone reductase) 유도활성을 살펴본 결과, 농도가 증가함에 따라 각각 1.36, 1.52, 1.67, 1.81 배 증가하였다. 상기한 결과를 통해서, 황금 추출물이 퀴논 리덕타아제 유도활성을 갖음을 알수 있었다.According to the accompanying drawings, the yellow gold extract was treated with hepatic cells (Hepa 1c1c7 cells) of mice at concentrations of 25, 50, 75, and 100 ㎍ / ml, and then examined for quinone reductase induction activity. As the concentration increased, they increased 1.36, 1.52, 1.67, and 1.81 fold, respectively. Through the above results, it was found that the golden extract has quinone reductase inducing activity.

실험예 2 : 스프로그 도올리계 쥐를 이용한 퀴논 리덕타아제의 저해활성 측정Experimental Example 2 Measurement of Inhibitory Activity of Quinone Reductase Using Splog Dooli Rats

스프로그-도올리(Sprague-Dawley)계 쥐(rat)에게 황금 추출물을 정상군을 포함하여 총 5군으로 나누어 시험하되, 투여량을 각각 0, 200, 500, 1000 ㎎/㎏로하여 2주간에 걸쳐서 경구투여하였다. 그리고, 쥐의 간을 취하여 호모게나이징 완충액[homogenizing buffer(0.25 M sucrose, pH 7.4)]로 균질화한 후, 9,000 x g에서 20분간 원심분리(4℃)하여 상등액을 취하고 다시 100,000 x g에서 1시간 동안 초원심분리(4℃)하여 얻은 상등액을 퀴논 리덕타아제(quinone reductase) 유도효과의 측정에 이용하였다. 그리고, 상기 실험예 1과 동일한 방법을 사용하여 퀴논 리덕타제 활성도를 계산하였고, 그 결과를 첨부도면 도 2에 나타내었다.Sprague-Dawley rats were tested with gold extract divided into 5 groups, including the normal group, and the dosage was 0, 200, 500, 1000 mg / kg for 2 weeks. Oral administration over Then, the liver of the mouse was homogenized with a homogenizing buffer (homogenizing buffer (0.25 M sucrose, pH 7.4)), centrifuged at 9,000 xg for 20 minutes (4 ° C), and the supernatant was taken again for 1 hour at 100,000 xg. The supernatant obtained by ultracentrifugation (4 ° C) was used for the measurement of quinone reductase induction effect. And quinone reductase activity was calculated using the same method as Experimental Example 1, and the results are shown in the accompanying drawings.

첨부도면 도 2에 의하면, 황금 추출물을 200, 500, 1000 ㎎/㎏ 처리시 각각1.2, 1.46, 1.59배 유도활성을 나타냈다. 이는 생쥐의 간세포계(Hepa 1c1c7 cell culture system)에서 뿐만 아니라, 생체계(in vivo system)에서도 황금 추출물에 의해 퀴논 리덕타아제(quinone reductase)의 활성이 유도되고 있음을 나타내고 있다.According to the accompanying drawings, when the gold extract 200, 500, 1000 mg / kg treatment showed 1.2, 1.46, 1.59-fold induction activity, respectively. This indicates that quinone reductase activity is induced by gold extract not only in mouse hepatic cell system (Hepa 1c1c7 cell culture system), but also in vivo system.

또한, 2주간 경구투여 후 체중을 측정한 결과, 정상군과 황금 추출물 투여군과의 특이할 만한 차이를 관찰할 수 없었으며, 최종 도살시에 실시된 주요 장기의 육안관찰에서도 황금 추출물은 정상군에 비해 변화를 유발시키지 못하였다.In addition, as a result of measuring the body weight after oral administration for 2 weeks, no significant difference was observed between the normal group and the golden extract administration group. It did not cause change.

그리고, 간독성의 지표인 혈중 글루타믹 파이루빅 트란스아미나아제[glutamic pyruvic transaminase(GPT)]와 글루타믹 옥살로아세틱 트란스아미나아제[glutamic oxaloacetic transaminase(GOT)〕 활성을 통상적인 방법을 사용하여 측정한 결과에서도 정상군에 비하여 유의성 있는 차이를 보이지 않았다.In addition, blood glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) activities, which are indicators of hepatotoxicity, were prepared using conventional methods. The measured results did not show any significant difference compared to the normal group.

제조예 1 : 츄잉껌(A)의 제조Preparation Example 1 Preparation of Chewing Gum (A)

껌베이스 20 %Gum base 20%

설탕 76.36 ∼ 76.76 %Sugar 76.36-76.76%

황금 추출물(실시예) 0.24 ∼ 0.64 %Golden extract (Example) 0.24-0.64%

후르츠향 1 %1% fruit flavor

물 2 %Water 2%

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 츄잉껌을 제조하였다.Chewing gum was prepared using the conventional method according to the composition and content.

제조예 2 : 츄잉껌(B)의 제조Preparation Example 2 Preparation of Chewing Gum (B)

껌 베이스 20 ∼ 30 %Gum base 20-30%

솔비톨 66.86 ∼ 77.26 %Sorbitol 66.86-77.26%

황금 추출물(실시예) 0.24 ∼ 0.64 %Golden extract (Example) 0.24-0.64%

페퍼민트 후레버 2.5 %Peppermint Flavor 2.5%

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 츄잉껌을 제조하였다.Chewing gum was prepared using the conventional method according to the composition and content.

제조예 3 : 캔디(A)의 제조Preparation Example 3 Preparation of Candy (A)

설탕 50 ∼ 60 %50 to 60% sugar

물엿 39.26 ∼ 49.66 %Starch syrup 39.26-49.66%

황금 추출물(실시예) 0.24 ∼ 0.64 %Golden extract (Example) 0.24-0.64%

오렌지향 0.1 %Orange flavor 0.1%

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 캔디를 제조하였다.Candy was prepared using the conventional method according to the composition and content.

제조예 4 : 캔디(B)의 제조Preparation Example 4 Preparation of Candy (B)

말티톨 50 ∼ 60 %Maltitol 50-60%

환원물엿 39.22 ∼ 49.62 %Reduced syrup 39.22-49.62%

황금 추출물(실시예) 0.24 ∼ 0.64 %Golden extract (Example) 0.24-0.64%

천연허브향 0.14 %Natural Herbal Flavor 0.14%

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 캔디를 제조하였다.Candy was prepared using the conventional method according to the composition and content.

제조예 5 : 비스켓의 제조Preparation Example 5 Preparation of Biscuits

박력1급 88 ㎏Force Class 1 88 kg

중력1급 76.4 ㎏Gravity First Class 76.4 ㎏

정백당 16.5 ㎏16.5 kg per white

식염 2.5 ㎏2.5 kg of salt

포도당 2.7 ㎏2.7 kg of glucose

팜쇼트닝 40.5 ㎏Palm shortening 40.5 kg

암모 5.3 ㎏5.3 kg of ammo

중조 0.6 ㎏Medium kg 0.6 kg

중아황산나트륨 0.55 ㎏0.55 kg sodium bisulfite

쌀가루 5.0 ㎏Rice flour 5.0 kg

비타민 B1 0.003 ㎏Vitamin B1 0.003 kg

비타민 B2 0.003 ㎏0.003 kg of vitamin B2

밀크향 0.16 ㎏Milk Flavor 0.16 ㎏

물 71.1 ㎏71.1 kg of water

전지분유 4 ㎏Whole milk powder 4 kg

대용분유 1 ㎏Substitute powder 1 kg

제일인산칼슘 0.1 ㎏0.1 kg of calcium phosphate

살포염 1 ㎏Spray salt 1 kg

분무유 25 ㎏25 kg of spray oil

황금 추출물(실시예) 0.1 ∼ 0.5 ㎏Golden extract (example) 0.1-0.5 kg

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 비스켓을 제조하였다.Biscuits were prepared using conventional methods according to the composition and content.

제조예 6 : 아이스크림의 제조Preparation Example 6 Preparation of Ice Cream

유지방 10.0 %Milkfat 10.0%

무지유고형분 10.8 %Non-fat solids 10.8%

설탕 12.0 %Sugar 12.0%

물엿 3.0 %Starch syrup 3.0%

유화안정제(스팬,span) 0.5 %Emulsifying stabilizer (span) 0.5%

향료(스트로베리) 0.15 %Spices (Strawberries) 0.15%

물 63.31 ∼ 62.91 %Water 63.31-62.91%

황금 추출물(실시예) 0.24 ∼ 0.64 %Golden extract (Example) 0.24-0.64%

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 아이스크림을 제조하였다.Ice cream was prepared by the conventional method according to the composition and content.

제조예 7 : 음료의 제조Preparation Example 7 Preparation of Beverage

꿀 522 ㎎522 mg of honey

치옥토산아미드 5 ㎎Chioctosanamide 5 mg

니코틴산아미드 10 ㎎Nicotinamide 10 mg

염산리보플라빈나트륨 3 ㎎Riboflavin Sodium Hydrochloride 3 mg

염산피리독신 2 ㎎Pyridoxine hydrochloride 2 mg

이노시톨 30 ㎎Inositol 30 mg

오르트산 50 ㎎Orthoic acid 50 mg

황금 추출물(실시예) 0.48 ∼ 1.28 ㎎Golden extract (Example) 0.48-1.28 mg

물 200 ㎖200 ml of water

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 음료를 제조하였다.The beverage was prepared by the conventional method according to the composition and content.

제조예 8 : 소세지의 제조Preparation Example 8 Preparation of Sausage

돈육 63.6 %Pork 63.6%

계육 27.5 %Chicken 27.5%

전분 3.5 %Starch 3.5%

대두단백 1.7 %Soy Protein 1.7%

식염 1.62 %Saline 1.62%

포도당 0.5 %Glucose 0.5%

기타첨가물(글리세린) 0.94 ∼ 1.34 %Other additives (glycerine) 0.94-1.34%

황금 추출물(실시예) 0.24 ∼ 0.64 %Golden extract (Example) 0.24-0.64%

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 소세지를 제조하였다.Sausage was prepared using the conventional method according to the composition and content.

제조예 9 : 쵸코렛의 제조Preparation Example 9 Preparation of Chocolate

설탕 34.36 ∼ 34.76 %Sugar 34.36-34.76%

코코아 버터 34 %Cocoa Butter 34%

코코아 매스 15 %Cocoa Mass 15%

코코아 파우다 15 %Cocoa Powder 15%

레시틴 0.5 %Lecithin 0.5%

바닐라향 0.5 %0.5% vanilla

황금 추출물(실시예) 0.24 ∼ 0.64 %Golden extract (Example) 0.24-0.64%

상기 조성 및 함량으로하여 통상적인 방법을 사용하여 초코렛을 제조하였다.Chocolate was prepared using the conventional method according to the composition and content.

이와같이 본 발명은 황금 추출물을 배합한 각종 음식물(예컨대 츄잉껌, 캔디, 비스켓, 아이스크림, 음료, 소세지, 쵸코렛 등)을 제조함으로써 암 예방효과가 있는 기능성식품을 제공할 수 있는 것이다.As described above, the present invention can provide a functional food having cancer prevention effect by preparing various foods (eg, chewing gum, candy, biscuits, ice cream, beverages, sausages, chocolates, etc.) containing golden extracts.

상술한 바와 같이, 본 발명은 황금 추출물이 퀴논 리덕타아제(Quinone reductase)의 활성을 유도하여 암예방 효과를 가짐을 확인하였고, 이를 츄잉껌, 캔디, 비스켓, 아이스크림, 음료, 소세지 및 쵸코렛 등의 음식물에 함께 배합함으로써, 청소년, 성인 및 노인층의 광범위한 계층까지 언제 어디서나 늘 간편하게 섭취할 수 있어서 지속적인 음용효과를 기대할 수 있는 것이다.As described above, the present invention was confirmed that the golden extract has the anti-cancer effect by inducing the activity of quinone reductase (Quinone reductase), it is chewing gum, candy, biscuits, ice cream, beverages, sausages and foods such as chocolate By blending together, a wide range of adolescents, adults and seniors can be easily consumed anytime, anywhere, and can be expected to have a continuous drinking effect.

Claims (3)

황금 추출물로 이루어진 퀴논 리덕타아제(quinone reductase)의 활성 유도물질.Activity inducer of quinone reductase consisting of golden extract. 황금 추출물이 퀴논 리덕타아제(quinone reductase)에 대한 활성 유도물질로 전체 조성에 대해 0.1 ∼ 1.0 중량% 함유된 것임을 특징으로 하는 황금 추출물을 함유하는 음식물.Food extract containing golden extract, characterized in that the golden extract is contained 0.1 to 1.0% by weight based on the total composition as an active inducer for quinone reductase. 제 2 항에 있어서, 상기 음식물은 츄잉껌, 캔디, 비스켓, 아이스크림, 음료, 소세지 및 쵸코렛인 것임을 특징으로 하는 황금 추출물을 함유하는 음식물.3. The food containing gold extract according to claim 2, wherein the food is chewing gum, candy, biscuits, ice cream, beverages, sausages and chocolates.
KR1019990018077A 1999-05-19 1999-05-19 Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity KR100314608B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019990018077A KR100314608B1 (en) 1999-05-19 1999-05-19 Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990018077A KR100314608B1 (en) 1999-05-19 1999-05-19 Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity

Publications (2)

Publication Number Publication Date
KR20000074271A KR20000074271A (en) 2000-12-15
KR100314608B1 true KR100314608B1 (en) 2001-11-22

Family

ID=19586556

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990018077A KR100314608B1 (en) 1999-05-19 1999-05-19 Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity

Country Status (1)

Country Link
KR (1) KR100314608B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100413964B1 (en) * 2000-10-06 2004-01-13 주식회사 에이티엔씨 Composition for preventing and treating cancer comprising isolated compounds and extracts from angelica koreana max and isolating methods thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100708214B1 (en) * 2005-01-17 2007-04-17 홍해옥 Method for preparing rice containing Scutellaria baicalensis
KR100823233B1 (en) * 2007-07-23 2008-04-18 (주)구룡촌 Method for manufacturing of gold kwamegi

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6450822A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Production of 'ougon' extract
KR940011006A (en) * 1992-11-12 1994-06-20 정종평 Periodontal disease prevention and therapeutic composition comprising golden extract as an active ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6450822A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Production of 'ougon' extract
KR940011006A (en) * 1992-11-12 1994-06-20 정종평 Periodontal disease prevention and therapeutic composition comprising golden extract as an active ingredient

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100413964B1 (en) * 2000-10-06 2004-01-13 주식회사 에이티엔씨 Composition for preventing and treating cancer comprising isolated compounds and extracts from angelica koreana max and isolating methods thereof

Also Published As

Publication number Publication date
KR20000074271A (en) 2000-12-15

Similar Documents

Publication Publication Date Title
Rhodes Physiologically-active compounds in plant foods: an overview
CA2354042C (en) Bioflavonoids, anthocyanins and phenolic compounds from cherries for inhibiting inflammation
KR101443230B1 (en) Composition for controlling blood pressure, regulating blood sugar and improving liver function comprising extract of Dendropanax morbiferus
Cariño-Cortés et al. Antimutagenicity of Stevia pilosa and Stevia eupatoria evaluated with the Ames test
US6991811B1 (en) Echinacea induction of phase II enzymes
Elhassaneen Stevia (Stevia rebaudiana) leaves: chemical composition, bioactive compounds, antioxidant activities, antihyperglycemic and antiatherogenic effects
KR100919625B1 (en) The composition comprising the extract or purified extract of Magnolia cortex for preventing and treating fatty liver diseases, and a method for preparing purified extract
KR101209574B1 (en) Pharmaceutical compositions and health functional foods compositions for the improvement of liver functions containing compound isolated from Youngia denticulata as an active ingredient
KR100314608B1 (en) Methods and foods using the extract of Scutellaria baicalensis as an inductive material of Quinone reductase activity
KR100900343B1 (en) A Composition comprising the extract of Aralia continentalis improving cytotoxicity and liver injury for preventing and treating of liver disease
Kumari et al. Metabolite profiling of the leaf extract reveals the antioxidant and nutraceuticals potential of the halophyte Salvadora persica
KR100749941B1 (en) Composition and food of liver cancer chemoprevention with extracts of Wasabia japonica
KR20140088969A (en) A Composition Comprising the Fermentate of Puerariae Radix extract for protecting liver damage
KR100998573B1 (en) Compositions of health functional foods for prevention of cancer containing Aster koraiensis extracts, fractions, the isolated Gymnasterkoreaynes derivatives therefrom or the pharmaceutically acceptable salts as an active ingredient
US20190030111A1 (en) Detoxifying composition for oral administration and method for preparing same
KR100547554B1 (en) A composition containing thawed bark, brownish, sumac extract having anti-inflammatory activity
KR100803385B1 (en) Composition and food for prevention of disease to nerve system with extracts of Wasabia japonica
KR100765419B1 (en) Health care composition comprising saucerneol b isolated from saururus chinensis for the prevention and alleviation of inflammatory, allergy and asthma diseases
KR100523462B1 (en) Composition comprising the extract of Astilbe rubra or Astilbic acid and Peltoboykinolic acid derivatives having anti-inflammatory or anti-allergic activity
KR20050089787A (en) Pharmaceutical composition comprising the extract of Kalopanax pictus, Pueraria thunbergiana and Rhus verniciflua having anti-inflammatory activity.
KR100523463B1 (en) Composition comprising the extract of Astilbe rubra or Astilbic acid and Peltoboykinolic acid derivatives having anti-inflammatory or anti-allergic activity
Ferrara Feijoa Sellowiana: characteristics and pharmacological activities
KR20140088970A (en) A Composition Comprising the Fermentate of Puerariae Radix extract for protecting liver damage
KR101092602B1 (en) Compositions for prevention and improvement of cancer containing the extracts and fractions of wild plants as an active ingredient
Kodikara A comprehensive metabolomic-assisted investigation of bioactive phenolic and lipophilic compounds in underutilized Canadian wild berries

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090115

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee